Literature DB >> 9850934

Lymphocytes as cell model to study apoptosis in Alzheimer's disease: vulnerability to programmed cell death appears to be altered.

A Eckert1, C W Cotman, R Zerfass, M Hennerici, W E Müller.   

Abstract

Recent evidence indicates that programmed cell death (apoptosis) may contribute to neuronal death in Alzheimer's disease (AD). In situ data derived from post mortem brain tissue indicate that DNA fragmentation which represents an important and typical apoptotic feature is markedly increased in brain cells of AD patients compared to controls. Furthermore, in vitro studies demonstrate that the peptide beta-amyloid (A beta) and its fragments induce apoptosis in neuronal cell cultures. One possible mechanism initiating apoptosis could be free radical generation by the peptide leading to oxidative stress. In a wide range of cell types common morphological and molecular events occur during apoptosis and several genes appear to be involved. Particularly in lymphocytes, apoptosis plays an important physiological role. Our data demonstrate that similar oxidative stressors induce apoptosis in mature human lymphocytes as in neurons. In addition, first evidence indicates that susceptibility to apoptosis is altered in lymphocytes from AD patients compared to non-demented controls. Our preliminary findings suggest that changes of the individual sensitivity to undergo cellular apoptosis are already detectable in lymphocytes from AD patients, probably as a consequence of genetic as well as other risk factors. Therefore, this biochemical marker might have the potential for identifying individuals at risk of the diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850934     DOI: 10.1007/978-3-7091-7508-8_25

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  10 in total

1.  Defects of immune regulation in the presenilin-1 mutant knockin mouse.

Authors:  Grant A Morgan; Qing Guo; Sic L Chan; Devin S Gary; Barbara A Osborne; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Beta-amyloid toxicity in embryonic rat astrocytes.

Authors:  Poincyane Assis-Nascimento; Karen M Jarvis; Jeremy R Montague; Laura M Mudd
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

3.  Comparative studies on [Ca2+]i-level of fibroblasts from Alzheimer patients and control individuals.

Authors:  A Palotás; J Kálmán; G Laskay; A Juhász; Z Janka; B Penke
Journal:  Neurochem Res       Date:  2001-07       Impact factor: 3.996

4.  Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production.

Authors:  Gero P Hooff; Imke Peters; W Gibson Wood; Walter E Müller; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2010-04-21       Impact factor: 5.590

Review 5.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

6.  The effect of citalopram on gene expression profile of Alzheimer lymphocytes.

Authors:  András Palotás; László G Puskás; Klára Kitajka; Miklós Palotás; József Molnár; Magdolna Pákáski; Zoltán Janka; Botond Penke; János Kálmán
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

7.  Beta-amyloid toxicity and reversal in embryonic rat septal neurons.

Authors:  Karen Jarvis; Poincyane Assis-Nascimento; Laura M Mudd; Jeremy R Montague
Journal:  Neurosci Lett       Date:  2007-08-09       Impact factor: 3.046

8.  Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.

Authors:  Timothy R Mhyre; Rebekah Loy; Pierre N Tariot; Louis A Profenno; Kathleen A Maguire-Zeiss; Dabao Zhang; Paul D Coleman; Howard J Federoff
Journal:  Neurobiol Aging       Date:  2007-05-22       Impact factor: 4.673

Review 9.  Changes in the immune system in depression and dementia: causal or coincidental effects?

Authors:  Brian E Leonard; Ayemu Myint
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

10.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.